Integrin αvβ6 sets the stage for colorectal cancer metastasis

Cancer and Metastasis Reviews

Volumn 34, Issue 4, 2015, Pages 715-734

  Cantor, D I ^a   Cheruku, H R ^a   Nice, E C ^b   Baker, M S ^a  

^a MACQUARIE UNIVERSITY   (Australia)

^b MONASH UNIVERSITY   (Australia)

Author keywords

Colorectal cancer; Metastatic transformation; 6 integrin

Indexed keywords

ALPHA5 INTEGRIN; ALPHAVBETA6 INTEGRIN; BETA6 INTEGRIN; FLUOROURACIL; IMMUNOLIPOSOME; INITIATION FACTOR 4E; MITOGEN ACTIVATED PROTEIN KINASE 1; PROTEOME; STROMAL CELL DERIVED FACTOR 1ALPHA; TRANSCRIPTION FACTOR ETS 1; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; UROKINASE RECEPTOR; CXCL12 PROTEIN, HUMAN; INTEGRIN; STROMAL CELL DERIVED FACTOR 1; TRANSFORMING GROWTH FACTOR BETA; TUMOR ANTIGEN; UROKINASE;

ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CELL MIGRATION; CELL SURFACE; COLORECTAL CANCER; ENZYME ACTIVATION; EXOSOME; GENETIC REGULATION; HUMAN; INTRACELLULAR SIGNALING; METASTASIS; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; CELL MOTION; COLORECTAL TUMOR; GENETICS; METABOLISM; PATHOLOGY;

ANTIGENS, NEOPLASM; CELL MOVEMENT; CHEMOKINE CXCL12; COLORECTAL NEOPLASMS; EUKARYOTIC INITIATION FACTOR-4E; HUMANS; INTEGRINS; NEOPLASM METASTASIS; PROMOTER REGIONS, GENETIC; TRANSFORMING GROWTH FACTOR BETA; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 84958891087     PISSN: 01677659     EISSN: 15737233     Source Type: Journal    
DOI: 10.1007/s10555-015-9591-z     Document Type: Article

References (116)

1. Xu, M., Chen, X., Yin, H., Yin, L., Liu, F., Fu, Y., et al. (2015). Cloning and characterization of the human integrin beta6 gene promoter. PloS One, 10(3), e0121439. doi:10.1371/journal.pone.0121439.
2. Ramos, D. M., But, M., Regezi, J., Schmidt, B. L., Atakilit, A., Dang, D., et al. (2002). Expression of integrin beta 6 enhances invasive behavior in oral squamous cell carcinoma. Matrix Biology, 21(3), 297–307.
3. Arnaout, M. A., Goodman, S. L., & Xiong, J. P. (2007). Structure and mechanics of integrin-based cell adhesion. Current Opinion in Cell Biology, 19(5), 495–507. doi:10.1016/j.ceb.2007.08.002.
4. Zhang, C., Liu, J., Jiang, X., Haydar, N., Zhang, C., Shan, H., et al. (2013). Modulation of integrin activation and signaling by alpha1/alpha1′-helix unbending at the junction. Journal of Cell Science, 126(Pt 24), 5735–5747. doi:10.1242/jcs.137828.
5. Campbell, I. D., & Humphries, M. J. (2011). Integrin structure, activation, and interactions. Cold Spring Harbor Perspectives in Biology, 3(3), doi:10.1101/cshperspect.a004994.
6. Ganguly, K. K., Pal, S., Moulik, S., & Chatterjee, A. (2013). Integrins and metastasis. Cell Adhesion & Migration, 7(3), 251–261. doi:10.4161/cam.23840.
7. Zaidel-Bar, R., Itzkovitz, S., Ma'ayan, A., Iyengar, R., & Geiger, B. (2007). Functional atlas of the integrin adhesome. Nature Cell Biology, 9(8), 858–867. doi:10.1038/ncb0807-858.
8. Bouaouina, M., Harburger, D. S., & Calderwood, D. A. (2012). Talin and signaling through integrins. Methods in Molecular Biology, 757, 325–347. doi:10.1007/978-1-61779-166-6_20.
9. Mitra, S. K., & Schlaepfer, D. D. (2006). Integrin-regulated FAK-Src signaling in normal and cancer cells. Current Opinion in Cell Biology, 18(5), 516–523. doi:10.1016/j.ceb.2006.08.011.
10. Ahmed, N., Pansino, F., Baker, M., Rice, G., & Quinn, M. (2002). Association between alphavbeta6 integrin expression, elevated p42/44 kDa MAPK, and plasminogen-dependent matrix degradation in ovarian cancer. Journal of Cellular Biochemistry, 84(4), 675–686. doi:10.1002/jcb.10080.
11. Giancotti, F. G., & Ruoslahti, E. (1999). Integrin signaling. Science, 285(5430), 1028–1032.
12. Cabodi, S., Di Stefano, P., Leal Mdel, P., Tinnirello, A., Bisaro, B., Morello, V., et al. (2010). Integrins and signal transduction. Advances in Experimental Medicine and Biology, 674, 43–54.
13. Jones, M. C., Humphries, J. D., Byron, A., Millon-Fremillon, A., Robertson, J., Paul, N. R., et al. (2015). Isolation of integrin-based adhesion complexes. Current Protocols in Cell Biology, 66, 981–9815. doi:10.1002/0471143030.cb0908s66.
14. Hynes, R. O. (2002). Integrins: bidirectional, allosteric signaling machines. Cell, 110(6), 673–687.
15. Montanez, E., Ussar, S., Schifferer, M., Bosl, M., Zent, R., Moser, M., et al. (2008). Kindlin-2 controls bidirectional signaling of integrins. Genes and Development, 22(10), 1325–1330. doi:10.1101/gad.469408.
16. Calderwood, D. A., Campbell, I. D., & Critchley, D. R. (2013). Talins and kindlins: partners in integrin-mediated adhesion. Nature Reviews Molecular Cell Biology, 14(8), 503–517. doi:10.1038/nrm3624.
17. Rognoni, E., Widmaier, M., Jakobson, M., Ruppert, R., Ussar, S., Katsougkri, D., et al. (2014). Kindlin-1 controls Wnt and TGF-beta availability to regulate cutaneous stem cell proliferation. Nature Medicine, 20(4), 350–359. doi:10.1038/nm.3490.
18. Abram, C. L., & Lowell, C. A. (2009). The ins and outs of leukocyte integrin signaling. Annual Review of Immunology, 27, 339–362. doi:10.1146/annurev.immunol.021908.132554.
19. Wegener, K. L., Partridge, A. W., Han, J., Pickford, A. R., Liddington, R. C., Ginsberg, M. H., et al. (2007). Structural basis of integrin activation by talin. Cell, 128(1), 171–182. doi:10.1016/j.cell.2006.10.048.
20. Morse, E. M., Brahme, N. N., & Calderwood, D. A. (2014). Integrin cytoplasmic tail interactions. Biochemistry, 53(5), 810–820. doi:10.1021/bi401596q.
21. Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., et al. (2015). Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. International Journal of Cancer, 136(5), E359–E386. doi:10.1002/ijc.29210.
22. Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011). Global cancer statistics. CA: A Cancer Journal for Clinicians, 61(2), 69–90. doi:10.3322/caac.20107.
23. Dhanapal, R., Saraswathi, T., & Govind, R. N. (2011). Cancer cachexia. Journal of Oral and Maxillofacial Pathology, 15(3), 257–260. doi:10.4103/0973-029X.86670.
24. Agrez, M., Chen, A., Cone, R. I., Pytela, R., & Sheppard, D. (1994). The alpha v beta 6 integrin promotes proliferation of colon carcinoma cells through a unique region of the beta 6 cytoplasmic domain. Journal of Cell Biology, 127(2), 547–556.
25. Hazelbag, S., Kenter, G. G., Gorter, A., Dreef, E. J., Koopman, L. A., Violette, S. M., et al. (2007). Overexpression of the alpha v beta 6 integrin in cervical squamous cell carcinoma is a prognostic factor for decreased survival. Journal of Pathology, 212(3), 316–324. doi:10.1002/path.2168.
26. Ramos, D. M., Dang, D., & Sadler, S. (2009). The role of the integrin alpha v beta6 in regulating the epithelial to mesenchymal transition in oral cancer. Anticancer Research, 29(1), 125–130.
27. Sun, Q., Sun, F., Wang, B., Liu, S., Niu, W., Liu, E., et al. (2014). Interleukin-8 promotes cell migration through integrin alphavbeta6 upregulation in colorectal cancer. Cancer Letters. doi:10.1016/j.canlet.2014.08.021.
28. Ahmed, N., Niu, J., Dorahy, D. J., Gu, X., Andrews, S., Meldrum, C. J., et al. (2002). Direct integrin alphavbeta6-ERK binding: implications for tumour growth. Oncogene, 21(9), 1370–1380. doi:10.1038/sj.onc.1205286.
29. Bates, R. C. (2005). Colorectal cancer progression: integrin alphavbeta6 and the epithelial-mesenchymal transition (EMT). Cell Cycle, 4(10), 1350–1352.
30. Bates, R. C., Bellovin, D. I., Brown, C., Maynard, E., Wu, B., Kawakatsu, H., et al. (2005). Transcriptional activation of integrin beta6 during the epithelial-mesenchymal transition defines a novel prognostic indicator of aggressive colon carcinoma. Journal of Clinical Investigation, 115(2), 339–347. doi:10.1172/JCI23183.
31. Binder, M. A. T. M. (2009). Drugs targeting integrins for cancer therapy. Expert Opinion on Drug Discovery, 4(3).
32. Liu, S., Liang, B., Gao, H., Zhang, F., Wang, B., Dong, X., et al. (2013). Integrin alphavbeta6 as a novel marker for diagnosis and metastatic potential of thyroid carcinoma. Head & Neck Oncology, 5(1), 7.
33. Bandyopadhyay, A., & Raghavan, S. (2009). Defining the role of integrin alphavbeta6 in cancer. Current Drug Targets, 10(7), 645–652.
34. Cantor, D., Slapetova, I., Kan, A., McQuade, L. R., & Baker, M. S. (2013). Overexpression of alphavbeta6 integrin alters the colorectal cancer cell proteome in favor of elevated proliferation and a switching in cellular adhesion that increases invasion. Journal of Proteome Research, 12(6), 2477–2490. doi:10.1021/pr301099f.
35. Ahmed, N., Riley, C., Rice, G. E., Quinn, M. A., & Baker, M. S. (2002). Alpha(v)beta(6) integrin-A marker for the malignant potential of epithelial ovarian cancer. Journal of Histochemistry and Cytochemistry, 50(10), 1371–1380.
36. Yang, G. Y., Xu, K. S., Pan, Z. Q., Zhang, Z. Y., Mi, Y. T., Wang, J. S., et al. (2008). Integrin alpha v beta 6 mediates the potential for colon cancer cells to colonize in and metastasize to the liver. Cancer Science, 99(5), 879–887. doi:10.1111/j.1349-7006.2008.00762.x.
37. Peng, C., Gao, H., Niu, Z., Wang, B., Tan, Z., Niu, W., et al. (2014). Integrin alphavbeta6 and transcriptional factor Ets-1 act as prognostic indicators in colorectal cancer. Cell & Bioscience, 4(1), 53. doi:10.1186/2045-3701-4-53.
38. Gill, S., Loprinzi, C. L., Sargent, D. J., Thome, S. D., Alberts, S. R., Haller, D. G., et al. (2004). Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? Journal of Clinical Oncology, 22(10), 1797–1806. doi:10.1200/JCO.2004.09.059.
39. Ahn, S. B., Mohamedali, A., Chan, C., Fletcher, J., Kwun, S. Y., Clarke, C., et al. (2014). Correlations between integrin alphanubeta6 expression and clinico-pathological features in stage B and stage C rectal cancer. PloS One, 9(5), e97248. doi:10.1371/journal.pone.0097248.
40. Davis, N. C., & Newland, R. C. (1983). Terminology and classification of colorectal adenocarcinoma: the Australian clinico-pathological staging system. Australian and New Zealand Journal of Surgery, 53(3), 211–221.
41. Enyu, L., Zhengchuan, N., Jiayong, W., Benjia, L., Qi, S., Ruixi, Q., et al. (2015). Integrin beta6 can be translationally regulated by eukaryotic initiation factor 4E: contributing to colonic tumor malignancy. Tumour Biology. doi:10.1007/s13277-015-3348-8.
42. Berkel, H. J., Turbat-Herrera, E. A., Shi, R., & de Benedetti, A. (2001). Expression of the translation initiation factor eIF4E in the polyp-cancer sequence in the colon. Cancer Epidemiology, Biomarkers and Prevention, 10(6), 663–666.
43. Seki, N., Takasu, T., Mandai, K., Nakata, M., Saeki, H., Heike, Y., et al. (2002). Expression of eukaryotic initiation factor 4E in atypical adenomatous hyperplasia and adenocarcinoma of the human peripheral lung. Clinical Cancer Research, 8(10), 3046–3053.
44. Nathan, C. O., Carter, P., Liu, L., Li, B. D., Abreo, F., Tudor, A., et al. (1997). Elevated expression of eIF4E and FGF-2 isoforms during vascularization of breast carcinomas. Oncogene, 15(9), 1087–1094. doi:10.1038/sj.onc.1201272.
45. Niu, Z., Wang, J., Muhammad, S., Niu, W., Liu, E., Peng, C., et al. (2014). Protein expression of eIF4E and integrin alphavbeta6 in colon cancer can predict clinical significance, reveal their correlation and imply possible mechanism of interaction. Cell & Bioscience, 4, 23. doi:10.1186/2045-3701-4-23.
46. De Benedetti, A., & Graff, J. R. (2004). eIF-4E expression and its role in malignancies and metastases. Oncogene, 23(18), 3189–3199. doi:10.1038/sj.onc.1207545.
47. Carroll, M., & Borden, K. L. (2013). The oncogene eIF4E: using biochemical insights to target cancer. Journal of Interferon and Cytokine Research, 33(5), 227–238. doi:10.1089/jir.2012.0142.
48. Badura, M., Braunstein, S., Zavadil, J., & Schneider, R. J. (2012). DNA damage and eIF4G1 in breast cancer cells reprogram translation for survival and DNA repair mRNAs. Proceedings of the National Academy of Sciences of the United States of America, 109(46), 18767–18772. doi:10.1073/pnas.1203853109.
49. Clarkson, B. K., Gilbert, W. V., & Doudna, J. A. (2010). Functional overlap between eIF4G isoforms in Saccharomyces cerevisiae. PloS One, 5(2), e9114. doi:10.1371/journal.pone.0009114.
50. Park, E. H., Zhang, F., Warringer, J., Sunnerhagen, P., & Hinnebusch, A. G. (2011). Depletion of eIF4G from yeast cells narrows the range of translational efficiencies genome-wide. BMC Genomics, 12, 68. doi:10.1186/1471-2164-12-68.
51. Ramirez-Valle, F., Braunstein, S., Zavadil, J., Formenti, S. C., & Schneider, R. J. (2008). eIF4GI links nutrient sensing by mTOR to cell proliferation and inhibition of autophagy. Journal of Cell Biology, 181(2), 293–307. doi:10.1083/jcb.200710215.
52. Silvera, D., Arju, R., Darvishian, F., Levine, P. H., Zolfaghari, L., Goldberg, J., et al. (2009). Essential role for eIF4GI overexpression in the pathogenesis of inflammatory breast cancer. Nature Cell Biology, 11(7), 903–908. doi:10.1038/ncb1900.
53. Tu, L., Liu, Z., He, X., He, Y., Yang, H., Jiang, Q., et al. (2010). Over-expression of eukaryotic translation initiation factor 4 gamma 1 correlates with tumor progression and poor prognosis in nasopharyngeal carcinoma. Molecular Cancer, 9, 78. doi:10.1186/1476-4598-9-78.
54. Comtesse, N., Keller, A., Diesinger, I., Bauer, C., Kayser, K., Huwer, H., et al. (2007). Frequent overexpression of the genes FXR1, CLAPM1 and EIF4G located on amplicon 3q26-27 in squamous cell carcinoma of the lung. International Journal of Cancer, 120(12), 2538–2544. doi:10.1002/ijc.22585.
55. Uhlen, M., Fagerberg, L., Hallstrom, B. M., Lindskog, C., Oksvold, P., Mardinoglu, A., et al. (2015). Proteomics. Tissue-based map of the human proteome. Science, 347(6220), 1260419. doi:10.1126/science.1260419.
56. Koistinen, P., & Heino, J. (2002). The selective regulation of alpha Vbeta 1 integrin expression is based on the hierarchical formation of alpha V-containing heterodimers. Journal of Biological Chemistry, 277(27), 24835–24841. doi:10.1074/jbc.M203149200.
57. Koivisto, L., Grenman, R., Heino, J., & Larjava, H. (2000). Integrins alpha5beta1, alphavbeta1, and alphavbeta6 collaborate in squamous carcinoma cell spreading and migration on fibronectin. Experimental Cell Research, 255(1), 10–17. doi:10.1006/excr.1999.4769.
58. Munger, J. S., Huang, X., Kawakatsu, H., Griffiths, M. J., Dalton, S. L., Wu, J., et al. (1999). The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis. Cell, 96(3), 319–328.
59. Busk, M., Pytela, R., & Sheppard, D. (1992). Characterization of the integrin alpha v beta 6 as a fibronectin-binding protein. Journal of Biological Chemistry, 267(9), 5790–5796.
60. Prieto, A. L., Edelman, G. M., & Crossin, K. L. (1993). Multiple integrins mediate cell attachment to cytotactin/tenascin. Proceedings of the National Academy of Sciences of the United States of America, 90(21), 10154–10158.
61. Huang, X., Wu, J., Spong, S., & Sheppard, D. (1998). The integrin alphavbeta6 is critical for keratinocyte migration on both its known ligand, fibronectin, and on vitronectin. Journal of Cell Science, 111(Pt 15), 2189–2195.
62. Sheppard, D. (2005). Integrin-mediated activation of latent transforming growth factor beta. Cancer and Metastasis Reviews, 24(3), 395–402. doi:10.1007/s10555-005-5131-6.
63. Annes, J. P., Rifkin, D. B., & Munger, J. S. (2002). The integrin alphaVbeta6 binds and activates latent TGFbeta3. FEBS Letters, 511(1-3), 65–68.
64. Singh, A., Greninger, P., Rhodes, D., Koopman, L., Violette, S., Bardeesy, N., et al. (2009). A gene expression signature associated with “K-Ras addiction” reveals regulators of EMT and tumor cell survival. Cancer Cell, 15(6), 489–500. doi:10.1016/j.ccr.2009.03.022.
65. Kang, H., Escudero-Esparza, A., Douglas-Jones, A., Mansel, R. E., & Jiang, W. G. (2009). Transcript analyses of stromal cell derived factors (SDFs): SDF-2, SDF-4 and SDF-5 reveal a different pattern of expression and prognostic association in human breast cancer. International Journal of Oncology, 35(1), 205–211.
66. Wang, B., Wang, W., Niu, W., Liu, E., Liu, X., Wang, J., et al. (2014). SDF-1/CXCR4 axis promotes directional migration of colorectal cancer cells through upregulation of integrin alphavbeta6. Carcinogenesis, 35(2), 282–291. doi:10.1093/carcin/bgt331.
67. Engl, T., Relja, B., Marian, D., Blumenberg, C., Muller, I., Beecken, W. D., et al. (2006). CXCR4 chemokine receptor mediates prostate tumor cell adhesion through alpha5 and beta3 integrins. Neoplasia, 8(4), 290–301. doi:10.1593/neo.05694.
68. Jones, J., Marian, D., Weich, E., Engl, T., Wedel, S., Relja, B., et al. (2007). CXCR4 chemokine receptor engagement modifies integrin dependent adhesion of renal carcinoma cells. Experimental Cell Research, 313(19), 4051–4065. doi:10.1016/j.yexcr.2007.07.001.
69. Xue, B., Wu, W., Huang, K., Xie, T., Xu, X., Zhang, H., et al. (2013). Stromal cell-derived factor-1 (SDF-1) enhances cells invasion by alphavbeta6 integrin-mediated signaling in ovarian cancer. Molecular and Cellular Biochemistry, 380(1-2), 177–184. doi:10.1007/s11010-013-1671-1.
70. Fedele, C., Singh, A., Zerlanko, B. J., Iozzo, R. V., & Languino, L. R. (2015). The alphavbeta6 integrin is transferred intercellularly via exosomes. Journal of Biological Chemistry, 290(8), 4545–4551. doi:10.1074/jbc.C114.617662.
71. Van Cutsem, E., & Costa, F. (2005). Progress in the adjuvant treatment of colon cancer: has it influenced clinical practice? JAMA, 294(21), 2758–2760. doi:10.1001/jama.294.21.2758.
72. Van Cutsem, E., Oliveira, J., & Group, E. G. W. (2009). Primary colon cancer: ESMO clinical recommendations for diagnosis, adjuvant treatment and follow-up. Annals of Oncology, 20(Suppl 4), 49–50. doi:10.1093/annonc/mdp126.
73. Liu, S., Wang, J., Niu, W., Liu, E., Wang, J., Peng, C., et al. (2013). The beta6-integrin-ERK/MAP kinase pathway contributes to chemo resistance in colon cancer. Cancer Letters, 328(2), 325–334. doi:10.1016/j.canlet.2012.10.004.
74. Liang, B., Shahbaz, M., Wang, Y., Gao, H., Fang, R., Niu, Z., et al. (2015). Integrinbeta6-targeted immunoliposomes mediate tumor-specific drug delivery and enhance therapeutic efficacy in colon carcinoma. Clinical Cancer Research, 21(5), 1183–1195. doi:10.1158/1078-0432.CCR-14-1194.
75. Zhao, Y. Z., Dai, D. D., Lu, C. T., Chen, L. J., Lin, M., Shen, X. T., et al. (2013). Epirubicin loaded with propylene glycol liposomes significantly overcomes multidrug resistance in breast cancer. Cancer Letters, 330(1), 74–83. doi:10.1016/j.canlet.2012.11.031.
76. Eberlein, C., Kendrew, J., McDaid, K., Alfred, A., Kang, J. S., Jacobs, V. N., et al. (2013). A human monoclonal antibody 264RAD targeting alphavbeta6 integrin reduces tumour growth and metastasis, and modulates key biomarkers in vivo. Oncogene, 32(37), 4406–4416. doi:10.1038/onc.2012.460.
77. Moore, K. M., Thomas, G. J., Duffy, S. W., Warwick, J., Gabe, R., Chou, P., et al. (2014). Therapeutic targeting of integrin alphavbeta6 in breast cancer. Journal of the National Cancer Institute, 106(8), doi:10.1093/jnci/dju169.
78. Lee, C., Lee, C., Lee, S., Siu, A., & Ramos, D. M. (2014). The cytoplasmic extension of the integrin beta6 subunit regulates epithelial-to-mesenchymal transition. Anticancer Research, 34(2), 659–664.
79. Weinacker, A., Chen, A., Agrez, M., Cone, R. I., Nishimura, S., Wayner, E., et al. (1994). Role of the integrin alpha v beta 6 in cell attachment to fibronectin. Heterologous expression of intact and secreted forms of the receptor. Journal of Biological Chemistry, 269(9), 6940–6948.
80. Cox, G., Steward, W. P., & O'Byrne, K. J. (1999). The plasmin cascade and matrix metalloproteinases in non-small cell lung cancer. Thorax, 54(2), 169–179.
81. Ahn, S. B., Mohamedali, A., Anand, S., Cheruku, H. R., Birch, D., Sowmya, G., et al. (2014). Characterization of the interaction between heterodimeric alphavbeta6 integrin and urokinase plasminogen activator receptor (uPAR) using functional proteomics. Journal of Proteome Research. doi:10.1021/pr500849x.
82. Pepper, M. S. (2001). Role of the matrix metalloproteinase and plasminogen activator-plasmin systems in angiogenesis. Arteriosclerosis, Thrombosis, and Vascular Biology, 21(7), 1104–1117.
83. Dutta, A., Li, J., Fedele, C., Sayeed, A., Singh, A., Violette, S. M., et al. (2015). alphavbeta6 integrin is required for TGFbeta1-mediated matrix metalloproteinase2 expression. Biochemistry Journal, 466(3), 525–536. doi:10.1042/BJ20140698.
84. Dang, D., Yang, Y., Li, X., Atakilit, A., Regezi, J., Eisele, D., et al. (2004). Matrix metalloproteinases and TGFbeta1 modulate oral tumor cell matrix. Biochemical and Biophysical Research Communications, 316(3), 937–942. doi:10.1016/j.bbrc.2004.02.143.
85. Allen, M. D., Thomas, G. J., Clark, S. E., Dawoud, M. M., Vallath, S., Payne, S. J., et al. (2013). Altered microenvironment promotes progression of pre-invasive breast cancer: myoepithelial expression of alphavbeta6 integrin in DCIS identifies high-risk patients and predicts recurrence. Clinical Cancer Research. doi:10.1158/1078-0432.CCR-13-1504.
86. Saldanha, R. G., Molloy, M. P., Bdeir, K., Cines, D. B., Song, X., Uitto, P. M., et al. (2007). Proteomic identification of lynchpin urokinase plasminogen activator receptor protein interactions associated with epithelial cancer malignancy. Journal of Proteome Research, 6(3), 1016–1028. doi:10.1021/pr060518n.
87. Sidenius, N., & Blasi, F. (2003). The urokinase plasminogen activator system in cancer: recent advances and implication for prognosis and therapy. Cancer and Metastasis Reviews, 22(2-3), 205–222.
88. Fishman, D. A., Kearns, A., Larsh, S., Enghild, J. J., & Stack, M. S. (1999). Autocrine regulation of growth stimulation in human epithelial ovarian carcinoma by serine-proteinase-catalysed release of the urinary-type-plasminogen-activator N-terminal fragment. Biochemistry Journal, 341(Pt 3), 765–769.
89. Xiong, J. P., Mahalingham, B., Alonso, J. L., Borrelli, L. A., Rui, X., Anand, S., et al. (2009). Crystal structure of the complete integrin alphaVbeta3 ectodomain plus an alpha/beta transmembrane fragment. Journal of Cell Biology, 186(4), 589–600. doi:10.1083/jcb.200905085.
90. Sowmya, G., Khan, J. M., Anand, S., Ahn, S. B., Baker, M. S., & Ranganathan, S. (2014). A site for direct integrin alphavbeta6.uPAR interaction from structural modelling and docking. Journal of Structural Biology. doi:10.1016/j.jsb.2014.01.001.
91. Weibrecht, I., Leuchowius, K. J., Clausson, C. M., Conze, T., Jarvius, M., Howell, W. M., et al. (2010). Proximity ligation assays: a recent addition to the proteomics toolbox. Expert Review of Proteomics, 7(3), 401–409. doi:10.1586/epr.10.10.
92. Thymiakou, E., & Episkopou, V. (2011). Detection of signaling effector-complexes downstream of bmp4 using PLA, a proximity ligation assay. Journal of Visualized Experiments, (49), doi:10.3791/2631.
93. Blasi, F., & Sidenius, N. (2009). The urokinase receptor: focused cell surface proteolysis, cell adhesion and signaling. FEBS Letters. doi:10.1016/j.febslet.2009.12.039.
94. Blasi, F., & Carmeliet, P. (2002). uPAR: a versatile signalling orchestrator. Nature Reviews Molecular Cell Biology, 3(12), 932–943. doi:10.1038/nrm977.
95. Annes, J. P., Chen, Y., Munger, J. S., & Rifkin, D. B. (2004). Integrin alphaVbeta6-mediated activation of latent TGF-beta requires the latent TGF-beta binding protein-1. Journal of Cell Biology, 165(5), 723–734. doi:10.1083/jcb.200312172.
96. Klass, B. R., Grobbelaar, A. O., & Rolfe, K. J. (2009). Transforming growth factor beta1 signalling, wound healing and repair: a multifunctional cytokine with clinical implications for wound repair, a delicate balance. Postgraduate Medical Journal, 85(999), 9–14. doi:10.1136/pgmj.2008.069831.
97. Zambruno, G., Marchisio, P. C., Marconi, A., Vaschieri, C., Melchiori, A., Giannetti, A., et al. (1995). Transforming growth factor-beta 1 modulates beta 1 and beta 5 integrin receptors and induces the de novo expression of the alpha v beta 6 heterodimer in normal human keratinocytes: implications for wound healing. Journal of Cell Biology, 129(3), 853–865.
98. Van Aarsen, L. A., Leone, D. R., Ho, S., Dolinski, B. M., McCoon, P. E., LePage, D. J., et al. (2008). Antibody-mediated blockade of integrin alpha v beta 6 inhibits tumor progression in vivo by a transforming growth factor-beta-regulated mechanism. Cancer Research, 68(2), 561–570. doi:10.1158/0008-5472.CAN-07-2307.
99. Dutta, A., Li, J., Lu, H., Akech, J., Pratap, J., Wang, T., et al. (2014). Integrin alphavbeta6 promotes an osteolytic program in cancer cells by upregulating MMP2. Cancer Research, 74(5), 1598–1608. doi:10.1158/0008-5472.CAN-13-1796.
100. Khan, S. A., Joyce, J., & Tsuda, T. (2012). Quantification of active and total transforming growth factor-beta levels in serum and solid organ tissues by bioassay. BMC Research Notes, 5, 636. doi:10.1186/1756-0500-5-636.
101. Leipnitz, G., Miyashita, C., Heiden, M., von Blohn, G., Kohler, M., & Wenzel, E. (1988). Reference values and variability of plasminogen in healthy blood donors and its relation to parameters of the fibrinolytic system. Haemostasis, 18(Suppl 1), 61–68.
102. Dvorak, H. F. (1986). Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. New England Journal of Medicine, 315(26), 1650–1659. doi:10.1056/NEJM198612253152606.
103. Teicher, B. A., & Fricker, S. P. (2010). CXCL12 (SDF-1)/CXCR4 pathway in cancer. Clinical Cancer Research, 16(11), 2927–2931. doi:10.1158/1078-0432.CCR-09-2329.
104. Hoesel, B., & Schmid, J. A. (2013). The complexity of NF-kappaB signaling in inflammation and cancer. Molecular Cancer, 12, 86. doi:10.1186/1476-4598-12-86.
105. Agarwal, E., Brattain, M. G., & Chowdhury, S. (2013). Cell survival and metastasis regulation by Akt signaling in colorectal cancer. Cellular Signalling, 25(8), 1711–1719. doi:10.1016/j.cellsig.2013.03.025.
106. Roy, H. K., Olusola, B. F., Clemens, D. L., Karolski, W. J., Ratashak, A., Lynch, H. T., et al. (2002). AKT proto-oncogene overexpression is an early event during sporadic colon carcinogenesis. Carcinogenesis, 23(1), 201–205.
107. Bravou, V., Klironomos, G., Papadaki, E., Taraviras, S., & Varakis, J. (2006). ILK over-expression in human colon cancer progression correlates with activation of beta-catenin, down-regulation of E-cadherin and activation of the Akt-FKHR pathway. Journal of Pathology, 208(1), 91–99. doi:10.1002/path.1860.
108. Latella, G., Vetuschi, A., Sferra, R., Speca, S., & Gaudio, E. (2013). Localization of alphanubeta6 integrin-TGF-beta1/Smad3, mTOR and PPARgamma in experimental colorectal fibrosis. European Journal of Histochemistry, 57(4), e40. doi:10.4081/ejh.2013.e40.
109. Francipane, M. G., & Lagasse, E. (2014). mTOR pathway in colorectal cancer: an update. Oncotarget, 5(1), 49–66.
110. Arcaro, A., & Guerreiro, A. S. (2007). The phosphoinositide 3-kinase pathway in human cancer: genetic alterations and therapeutic implications. Current Genomics, 8(5), 271–306. doi:10.2174/138920207782446160.
111. Su, C. C., Lin, Y. P., Cheng, Y. J., Huang, J. Y., Chuang, W. J., Shan, Y. S., et al. (2007). Phosphatidylinositol 3-kinase/Akt activation by integrin-tumor matrix interaction suppresses Fas-mediated apoptosis in T cells. Journal of Immunology, 179(7), 4589–4597.
112. Fleming, N. I., Jorissen, R. N., Mouradov, D., Christie, M., Sakthianandeswaren, A., Palmieri, M., et al. (2013). SMAD2, SMAD3 and SMAD4 mutations in colorectal cancer. Cancer Research, 73(2), 725–735. doi:10.1158/0008-5472.CAN-12-2706.
113. Xie, W., Rimm, D. L., Lin, Y., Shih, W. J., & Reiss, M. (2003). Loss of Smad signaling in human colorectal cancer is associated with advanced disease and poor prognosis. Cancer Journal, 9(4), 302–312.
114. Najdi, R., Holcombe, R. F., & Waterman, M. L. (2011). Wnt signaling and colon carcinogenesis: beyond APC. Journal of Carcinogenesis, 10, 5. doi:10.4103/1477-3163.78111.
115. Wang, S., Liu, Z., Wang, L., & Zhang, X. (2009). NF-kappaB signaling pathway, inflammation and colorectal cancer. Cellular and molecular immunology, 6(5), 327–334. doi:10.1038/cmi.2009.43.
116. Azare, J., Leslie, K., Al-Ahmadie, H., Gerald, W., Weinreb, P. H., Violette, S. M., et al. (2007). Constitutively activated Stat3 induces tumorigenesis and enhances cell motility of prostate epithelial cells through integrin beta 6. Molecular and Cellular Biology, 27(12), 4444–4453. doi:10.1128/MCB.02404-06.